Drugs & Aging

, Volume 21, Issue 2, pp 81–100

Role of Hydrogen Peroxide in the Aetiology of Alzheimer’s Disease

Implications for Treatment
Leading Article

Abstract

Hydrogen peroxide (H2O2) is a stable, uncharged and freely diffusable reactive oxygen species (ROS) and second messenger. The generation of H2O2 in the brain is relatively high because of the high oxygen consumption in the tissue. Alzheimer’s disease is a neurodegenerative disorder characterised by the appearance of amyloid-β (Aβ)-containing plaques and hyperphosphorylated tau-containing neurofibrillary tangles. The pathology of Alzheimer’s disease is also associated with oxidative stress and H2O2 is implicated in this and the neurotoxicity of the Aβ peptide. The ability for Aβ to generate H2O2, and interactions of H2O2 with iron and copper to generate highly toxic ROS, may provide a mechanism for the oxidative stress associated with Alzheimer’s disease. The role of heavy metals in Alzheimer’s disease pathology and the toxicity of the H2O2 molecule may be closely linked.

Drugs that prevent oxidative stress include antioxidants, modifiers of the enzymes involved in ROS generation and metabolism, metal chelating agents and agents that can remove the stimulus for ROS generation. In Alzheimer’s disease the H2O2 molecule must be considered a therapeutic target for treatment of the oxidative stress associated with the disease. The actions of H2O2 include modifications of proteins, lipids and DNA, all of which are effects seen in the Alzheimer’s disease brain and may contribute to the loss of synaptic function characteristic of the disease. The effectiveness of drugs to target this component of the disease pathology remains to be determined; however, metal chelators may provide an effective route and have the added bonus in the case of clioquinol of potentially reducing the Aβ load. Future research and development of agents that specifically target the H2O2 molecule or enzymes involved in its metabolism may provide the future route to Alzheimer’s disease therapy.

References

  1. 1.
    Fridovich I. Superoxide anion radical (O2−), Superoxide dismutases, and related matters. J Biol Chem 1997; 272: 18515–7PubMedCrossRefGoogle Scholar
  2. 2.
    Halliwell B. Role of free radicals in neurodegenerative diseases: therapeutic implications for antioxidant treatment. Drugs Aging 2001; 18: 685–716PubMedCrossRefGoogle Scholar
  3. 3.
    Halliwell B, Clement MV, Long LH. Hydrogen peroxide in the human body. FEBS Lett 2000; 486: 10–3PubMedCrossRefGoogle Scholar
  4. 4.
    Halliwell B, Gutteridge JMC. Free radicals in biology and medicine. 3rd ed. Oxford: University Press, 1999Google Scholar
  5. 5.
    Levine RL, Berlett BS, Moskovitz J, et al. Methionine residues may protect proteins from critical oxidative damage. Mech Ageing Dev 1999; 107: 323–32PubMedCrossRefGoogle Scholar
  6. 6.
    Hampton MB, Fadeel B, Orrenius S. Redox regulation of the caspases during apoptosis. Ann N Y Acad Sci 1998; 854: 328–35PubMedCrossRefGoogle Scholar
  7. 7.
    Borutaite V, Brown GC. Caspases are reversibly inactivated by hydrogen peroxide. FEBS Lett 2001; 500: 114–8PubMedCrossRefGoogle Scholar
  8. 8.
    Jackson MJ, Papa S, Bolanos J, et al. Antioxidants, reactive oxygen and nitrogen species, gene induction and mitochondrial function. Mol Aspects Med 2002; 23: 209–85PubMedCrossRefGoogle Scholar
  9. 9.
    Reth M. Hydrogen peroxide as second messenger in lymphocyte activation. Nat Immunol 2002; 3: 1129–34PubMedCrossRefGoogle Scholar
  10. 10.
    Sen CK, Sies H, Baeuerle PA, editors. Antioxidant and redox regulation of genes. San Diego (CA): Academic Press, 2000Google Scholar
  11. 11.
    Bowie A, O’Neill LAJ. Oxidative stress and nuclear factor-κB activation. Biochem Pharmacol 2000; 59: 13–23PubMedCrossRefGoogle Scholar
  12. 12.
    Perry G, Sayre LM, Atwood CS, et al. The role of iron and copper in the aetiology of neurodegenerative disorders. CNS Drugs 2002; 16: 339–52PubMedCrossRefGoogle Scholar
  13. 13.
    Schulz JB, Lindenau J, Seyfried J, et al. Glutathione, oxidative stress and neurodegeneration. Eur J Biochem 2000; 267: 4904–11PubMedCrossRefGoogle Scholar
  14. 14.
    Cadenas E, Davies KJA. Mitochondrial free radical generation, oxidative stress and aging. Free Radic Biol Med 2000; 29: 222–30PubMedCrossRefGoogle Scholar
  15. 15.
    Tarpey MM, Fridovich I. Methods of detection of vascular reactive species: nitric oxide, Superoxide, hydrogen peroxide, and peroxynitrite. Circ Res 2001; 89: 224–36PubMedCrossRefGoogle Scholar
  16. 16.
    Boveris A, Martino E, Stoppani AO. Evaluation of the horseradish peroxidase-scopoletin method for the measurement of hydrogen peroxide formation in biological systems. Anal Biochem 1977; 80: 145–58PubMedCrossRefGoogle Scholar
  17. 17.
    Hinkle PC, Butow RA, Racker E, et al. Partial resolution of the enzymes catalyzing oxidative phosphorylation, XV: reverse electron transfer in the flavin-cytochrome β region of the respiratory chain of beef heart submitochondrial particles. J Biol Chem 1967; 242: 5169–73PubMedGoogle Scholar
  18. 18.
    Sies H. Measurement of hydrogen peroxide formation in situ. Methods Enzymol 1981; 77: 15–20PubMedCrossRefGoogle Scholar
  19. 19.
    Hyslop PA, Sklar LA. A quantitative fluorimetric assay for the determination of oxidant production by polymorphonuclear leukocytes: its use in the simultaneous fluorimetric assay of cellular activation processes. Anal Biochem 1984; 141: 280–6PubMedCrossRefGoogle Scholar
  20. 20.
    Ruch W, Cooper PH, Baggiolini M. Assay of H2O2 production by macrophages and neutrophils with homovanillic acid and horseradish peroxidase. J Immunol Methods 1983; 63: 347–57PubMedCrossRefGoogle Scholar
  21. 21.
    Cohen G, Kim M, Ogwu V. A modified catalase assay suitable for a plate reader and for the analysis of brain cell cultures. J Neurosci Methods 1996; 67: 53–6PubMedCrossRefGoogle Scholar
  22. 22.
    Staniek K, Nohl H. H2O2 detection from intact mitochondria as a measure for one-electron reduction of dioxygen requires a non-invasive assay system. Biochim Biophys Acta 1999; 1413: 70–80PubMedCrossRefGoogle Scholar
  23. 23.
    Pick E, Keisari Y. A simple colorimetric method for the measurement of hydrogen peroxide produced by cells in culture. J Immunol Methods 1980; 38: 161–70PubMedCrossRefGoogle Scholar
  24. 24.
    Margoliash E, Novogrodsky A, Schejter A. Irreversible reaction of 3-amino-l: 2,4-triazole and related inhibitors with the protein catalase. Biochem J 1960; 74: 339–48PubMedGoogle Scholar
  25. 25.
    Kinnula VL, Mirza Z, Crapo JD, et al. Modulation of hydrogen peroxide release from vascular endothelial cells by oxygen. Am J Respir Cell Mol Biol 1993; 9: 603–9PubMedGoogle Scholar
  26. 26.
    Melnick LM. Iron. In: Kolthoff IM, Elving PJ, Sandeil EB, editors. Treatise on analytical chemistry. Part II: analytical chemistry of the elements. Vol. 2. New York (NY): Interscience Publishers, 1962: 247–310Google Scholar
  27. 27.
    Thurman RG, Ley HG, Scholz R. Hepatic microsomal ethanol oxidation: hydrogen peroxide formation and the role of catalase. Eur J Biochem 1972; 25: 420–30PubMedCrossRefGoogle Scholar
  28. 28.
    Shi M, Gozal E, Choy HA, et al. Extracellular glutathione and glutamyl-transpeptidase prevent H2O2-induced injury by 2,3-dimethoxy-1,4-naphthoquinone. Free Radic Biol Med 1993; 15: 57–67PubMedCrossRefGoogle Scholar
  29. 29.
    Tarpey MM, White CR, Suarez E, et al. Chemiluminescent detection of oxidants in vascular tissue: lucigenin but not coelenterazine enhances Superoxide formation. Circ Res 1999; 84: 1203–11PubMedCrossRefGoogle Scholar
  30. 30.
    Behl C, Davies JB, Lesley R, et al. Hydrogen peroxide mediates amyloid beta protein toxicity. Cell 1994; 77: 817–27PubMedCrossRefGoogle Scholar
  31. 31.
    Keston AS, Brandt R. The fluorometric analysis of ultramicro quantities of hydrogen peroxide. Anal Biochem 1965; 11: 1–5PubMedCrossRefGoogle Scholar
  32. 32.
    Elbaum D, Brzyska M, Bacia A, et al. Implication of novel biochemical property of β-amyloid. Biochem Biophys Res Commun 2000; 267: 733–8PubMedCrossRefGoogle Scholar
  33. 33.
    Brzyska M, Bacia A, Elbaum D. Oxidative and hydrolytic properties of β-amyloid. Eur J Biochem 2001; 268: 3443–54PubMedCrossRefGoogle Scholar
  34. 34.
    Ward RJ, Peters TJ. Free radicals. In: Marshall WJ, Bangert SK, editors. Clinical biohemistry, metabolic and clinical aspects. New York (NY): Churchill Livingstone, 1995: 765–77Google Scholar
  35. 35.
    Tamagno E, Aragno M, Parola M, et al. NT2 neurons, a classical model for Alzheimer’s disease, are highly susceptible to oxidative stress. Neuroreport 2000; 11: 1865–9PubMedCrossRefGoogle Scholar
  36. 36.
    Pratico D, Delanty N. Oxidative injury in diseases of the central nervous system: focus on Alzheimer’s disease. Am J Med 2000; 109: 577–85PubMedCrossRefGoogle Scholar
  37. 37.
    Butterfield DA, Yatin SM, Varadarajan S, et al. Amyloid β-peptide associated free radical oxidative stress, neurotoxicity, and Alzheimer’s disease. Methods Enzymol 1999; 309: 746–68PubMedCrossRefGoogle Scholar
  38. 38.
    Andrews AM, Ladenheim B, Epstein CJ, et al. Transgenic mice with high levels of Superoxide dismutase activity are protected from the neurotoxic effects of 2-NH2-MPTP on serotonergic and noradrenergic nerve terminals. Mol Pharmacol 1996; 50: 1511–9PubMedGoogle Scholar
  39. 39.
    Mikawa S, Kinouchi H, Kamii H, et al. Attenuation of acute and chronic damage following traumatic brain injury in copper, zinc-superoxide dismutase transgenic mice. J Neurosurgery 1996; 85: 885–91CrossRefGoogle Scholar
  40. 40.
    Chan PH, Kawase M, Murakami K, et al. Overexpression of SOD1 in transgenic rats protects vulnerable neurons against ischemic damage after global cerebral ischaemia and reperfusion. J Neurosci 1998; 18: 8292–9PubMedGoogle Scholar
  41. 41.
    Jayanthi S, Ladenheim B, Andrews AM, et al. Overexpression of human copper/zinc Superoxide dismutase in transgenic mice attenuates oxidative stress caused by methylenedioxy-methamphetamine (Ecstasy). Neuroscience 1999; 91: 1379–87PubMedCrossRefGoogle Scholar
  42. 42.
    Reaume AG, Elliott JL, Hoffman EK, et al. Motor neurons in Cu/Zn Superoxide dismutase-deficient mice develop normally but exhibit enhanced cell death after axonal injury. Nat Genet 1996; 13: 43–7PubMedCrossRefGoogle Scholar
  43. 43.
    Lebovitz RM, Zhang H, Vogel H, et al. Neurodegeneration, myocardial injury, and perinatal death in mitochondrial superoxide dismutase-deficient mice. Proc Natl Acad Sci U S A 1996; 93: 9782–7PubMedCrossRefGoogle Scholar
  44. 44.
    Melov S, Coskun P, Patel M, et al. Mitochondrial disease in Superoxide dismutase 2 mutant mice. Proc Natl Acad Sci U S A 1999; 96: 846–51PubMedCrossRefGoogle Scholar
  45. 45.
    Li Y, Huang IT, Carlson EJ, et al. Dilated cardiomyopathy and neonatal lethality in mutant mice lacking manganese superoxide dismutase. Nat Genet 1995; 11: 376–81PubMedCrossRefGoogle Scholar
  46. 46.
    Melov S, Schneider JA, Day BJ, et al. A novel neurological phenotype in mice lacking mitochondrial manganese superoxide dismutase. Nat Genet 1998; 18: 159–63PubMedCrossRefGoogle Scholar
  47. 47.
    Thiels E, Urban NN, Gonzalez-Burgos GR, et al. Impairment of long-term potentiation and associated memory in mice that overexpress extracellular Superoxide dismutase. J Neurosci 2000; 20: 7631–9PubMedGoogle Scholar
  48. 48.
    Levin ED, Brady TC, Hochrein EC, et al. Molecular manipulations of extracellular Superoxide dismutase: functional importance for learning. Behav Genet 1998; 28: 381–90PubMedCrossRefGoogle Scholar
  49. 49.
    Jain A, Martensson J, Stole E, et al. Glutathione deficiency leads to mitochondrial damage in brain. Proc Natl Acad Sci U S A 1991; 88: 1913–7PubMedCrossRefGoogle Scholar
  50. 50.
    Weisbrot-Lefkowitz M, Reuhl K, Perry B, et al. Overexpression of human glutathione peroxidase protects transgenic mice against focal cerebral ischaemia/reperfusion damage. Brain Res 1998; 53: 333–8CrossRefGoogle Scholar
  51. 51.
    Klivenyi P, Andreassen OA, Ferrante RJ, et al. Mice deficient in cellular glutathione peroxidase show increased vulnerability to malonate 3-nitropropionic acid, and MPTP. J Neurosci 2000; 20: 1–7PubMedGoogle Scholar
  52. 52.
    Sarafian TA, Verity MA, Vinters HV, et al. Differential expression of peroxiredoxin subtypes in human brain cell types. J Neurosci Res 1999; 56: 206–12PubMedGoogle Scholar
  53. 53.
    Takagi Y, Mitsui A, Nishiyama A, et al. Overexpression of thioredoxin in transgenic mice attenuates focal ischemic brain damage. Proc Natl Acad Sci U S A 1999; 96: 4131–6PubMedCrossRefGoogle Scholar
  54. 54.
    Mazzioti M, Perlmutter DH. Resistance to the apoptotic effect of aggregated amyloid-beta peptide in several different cell types including neuronal- and hepatoma-derived cell lines. Biochem J 1998; 332: 517–24Google Scholar
  55. 55.
    Sagara Y, Dargusch R, Klier FG, et al. Increased antioxidant enzyme activity in amyloid β protein-resistant cells. J Neurosci 1996; 16: 497–505PubMedGoogle Scholar
  56. 56.
    Milton NGN. Inhibition of catalase activity with 3-amino-triazole enhances the cytotoxicity of the Alzheimer’s amyloid-β peptide. Neurotoxicology 2001; 22: 767–74PubMedCrossRefGoogle Scholar
  57. 57.
    Dringen R. Metabolism and functions of glutathione in brain. Prog Neurobiol 2000; 62: 649–71PubMedCrossRefGoogle Scholar
  58. 58.
    Gilgun-Sherki Y, Melamed E, Offen D. Oxidative stress induced-neurodegenerative diseases: the need for antioxidants that penetrate the blood brain barrier. Neuropharmacology 2001; 40: 959–75PubMedCrossRefGoogle Scholar
  59. 59.
    Gupta R, Singh M, Sharma A. Neuroprotective effect of antioxidants on ischaemia and reperfusion-induced cerebral injury. Pharmacol Res 2003; 48: 209–15PubMedCrossRefGoogle Scholar
  60. 60.
    Azzi A, Stocker A. Vitamin E: non-antioxidant roles. Prog Lipid Res 2000; 39: 231–55PubMedCrossRefGoogle Scholar
  61. 61.
    Fillit HM, O’Connell AW, Brown WM, et al. Barriers to drug discovery and development for Alzheimer’s disease. Alzheimer Dis Assoc Disord 2002; 16Suppl. 1: S1–8PubMedCrossRefGoogle Scholar
  62. 62.
    Braak H, Braak E, Bohl J. Staging of Alzheimer-related cortical destruction. Eur Neurol 1993; 33: 403–8PubMedCrossRefGoogle Scholar
  63. 63.
    Jellinger KA. The neuropathological diagnosis of Alzheimer disease. J Neural Transm Suppl 1998; 53: 97–118PubMedCrossRefGoogle Scholar
  64. 64.
    Snowdon DA, Greiner LH, Mortimer JA, et al. Brain infarction and the clinical expression of Alzheimer disease: the Nun Study. JAMA 1997; 277: 813–7PubMedCrossRefGoogle Scholar
  65. 65.
    Davis DR, Anderton BH, Brion JP, et al. Oxidative stress induces dephosphorylation of tau in rat brain primary neuronal cultures. J Neurochem 1997; 68: 1590–7PubMedCrossRefGoogle Scholar
  66. 66.
    Olivieri G, Baysang G, Meier F, et al. N-acetyl-L-cysteine protects SHSY5Y neuroblastoma cells from oxidative stress and cell cytotoxicity: effects on beta-amyloid secretion and tau phosphorylation. J Neurochem 2001; 76: 224–33PubMedCrossRefGoogle Scholar
  67. 67.
    Arriagada P, Growdon JH, Hedley-Whyte ET, et al. Neurofibrillary tangles, but not plaques parallel duration and severity of Alzheimer’s disease. Neurology 1992; 42: 631–9PubMedCrossRefGoogle Scholar
  68. 68.
    Davies P. Neuronal abnormalities, not amyloid, are the cause of dementia in Alzheimer disease. In: Terry RD, Katzman R, Bick KL, editors. Alzheimer disease. New York: Raven Press Ltd, 1994: 327–33Google Scholar
  69. 69.
    Samuel W, Terry RD, DeTeresa R, et al. Clinical correlates of cortical and nucleus basalis pathology in Alzheimer dementia. Arch Neurol 1994; 51: 772–8PubMedCrossRefGoogle Scholar
  70. 70.
    Haugh MC, Probst A, Ulrich J, et al. Alzheimer neurofibrillary tangles contain phosphorylated and hidden neurofilament epitopes. J Neurol Neurosurg Psychiatry 1986; 49: 1213–20PubMedCrossRefGoogle Scholar
  71. 71.
    Goedert M. Tau protein and the neurofibrillary pathology of Alzheimer’s disease. Trends Neurosci 1993; 16: 460–5PubMedCrossRefGoogle Scholar
  72. 72.
    Ruben GC, Iqbal K, Grundke-Iqbal I, et al. The organization of the microtubule associated protein tau in Alzheimer paired helical filaments. Brain Res 1993; 602: 1–13PubMedCrossRefGoogle Scholar
  73. 73.
    Trojanowski JQ, Schmidt ML, Shin RW, et al. Altered tau and neurofilament proteins in neuro-degenerative diseases: diagnostic implications for Alzheimer’s disease and Lewy body dementias. Brain Pathol 1993; 3: 45–54PubMedCrossRefGoogle Scholar
  74. 74.
    Zemlan FP, Vogelsong GD, McLaughlin L, et al. Alzheimer’s paired helical filaments: amyloid precursor protein epitope mapping. Brain Res Bull 1994; 33: 387–92PubMedCrossRefGoogle Scholar
  75. 75.
    Goedert M, Jakes R, Spillantini MG, et al. Tau protein and Alzheimer’s disease. In: Hyams JS, Lloyd CW, editors. Microtubules, modern cell biology. New York: Wiley-Liss Inc, 1994: 183–200Google Scholar
  76. 76.
    Terry RD, Masliah E, Hansen LA. Structural basis of the cognitive alterations in Alzheimer disease. In: Terry RD, Katzman R, Bick RL, editors. Alzheimer disease. New York: Raven Press, 1994: 179–96Google Scholar
  77. 77.
    Terry RD, Davies P. Some morphological and biochemical aspects of Alzheimer’s disease. In: Samuel D, Algeri S, Gershon S, et al., editors. Aging of the brain, 22. New York: Raven Press, 1983: 47–59Google Scholar
  78. 78.
    Lee VMY, Balin BJ, Otvos Jr L, et al. A 68: a major subunit of paired helical filaments and derivatized form of normal tau. Science 1991; 251: 675–8PubMedCrossRefGoogle Scholar
  79. 79.
    Kosik KS, Greenberg SM. Tau protein and Alzheimer disease. In: Terry RD, Katzman R, Bick KL, editors. Alzheimer disease. New York: Raven Press, 1994: 335–44Google Scholar
  80. 80.
    Hue DP, Power D, Brion JP, et al. Immunochemistry and composition of neurofibrillary tangles. In: Davies DC, editor. Current problems in neurology II Alzheimer’s disease: towards an understanding of the aetiology and pathogenesis. London: John Libbey, 1989: 55–64Google Scholar
  81. 81.
    Pei JJ, Braak E, Braak H, et al. Localization of active forms of C-jun kinase (JNK) and p38 kinase in Alzheimer’s disease brains at different stages of neurofibrillary degeneration. J Alzheimers Dis 2001; 3: 41–8PubMedGoogle Scholar
  82. 82.
    Zhang L, Jope RS. Oxidative stress differentially modulates phosphorylation of ERK, p38 and CREB induced by NGF or EGF in PC12 cells. Neurobiol Aging 1999; 20: 271–8PubMedCrossRefGoogle Scholar
  83. 83.
    Ferrer I, Blanco R, Carmona M, et al. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J Neural Transm 2001; 108: 1397–415PubMedCrossRefGoogle Scholar
  84. 84.
    Savage MJ, Lin YG, Ciallella JR, et al. Activation of c-Jun N terminal kinase and p38 in an Alzheimer’s disease model is associated with amyloid deposition. J Neurosci 2002; 22: 3376–85PubMedGoogle Scholar
  85. 85.
    Pearson RCA, Esiri MM, Hiorns RW, et al. S. Anatomical correlates of the distribution of the pathological changes in the neocortex in Alzheimer’s disease. Proc Natl Acad Sci U S A 1985; 82: 4531–4PubMedCrossRefGoogle Scholar
  86. 86.
    Arnold SE, Hyman BT, Flory J, et al. The topographical and neuroanatomical distribution of neurofibrillary tangles and neuritic plaques in the cerebral cortex of patients with Alzheimer’s disease. Cereb Cortex 1991; 1: 103–16PubMedCrossRefGoogle Scholar
  87. 87.
    Mann DMA. The pathogenesis and progression of the pathological changes of Alzheimer’s disease. In: Davies DC, editor. Current problems in neurology II Alzheimer’s disease: towards an understanding of the aetiology and pathogenesis. London: John Libbey, 1989: 43–53Google Scholar
  88. 88.
    Braak H, Braak E. Neuropathological staging of Alzheimer related changes. Acta Neuropathol (Berl) 1991; 82: 239–59CrossRefGoogle Scholar
  89. 89.
    Ulrich J. Alzheimer changes in non demented patients younger than 65: possible early stages of Alzheimer’s disease and senile dementia of Alzheimer type. Ann Neurol 1985; 17: 273–7PubMedCrossRefGoogle Scholar
  90. 90.
    Hof PR, Perl DP, Loerzel AJ, et al. Neurofibrillary tangle distribution in the cerebral cortex of parkinsonism-dementia cases from Guam: differences with Alzheimer’s disease. Brain Res 1991; 564: 306–13PubMedCrossRefGoogle Scholar
  91. 91.
    Hof PR, Bouras C, Buee L, et al. Differential distribution of NFTs in the cerebral cortex of dementia pugilistica and Alzheimer’s disease. Acta Neuropathol (Berl) 1992; 85: 23–30CrossRefGoogle Scholar
  92. 92.
    Morrison JH, Lewis DA, Campbell MJ, et al. A monoclonal antibody to non-phosphorylated neurofilament protein marks the vulnerable cortical neurones in Alzheimer’s disease. Brain Res 1987; 416: 331–6PubMedCrossRefGoogle Scholar
  93. 93.
    Bouras C, Hof PR, Morrison JH. Neurofibrillary tangle densities in the hippocampal formation in a non-demented population define subgroups of patients with differential early pathological changes. Neurosci Lett 1993; 153: 131–5PubMedCrossRefGoogle Scholar
  94. 94.
    Price DL. New perspectives in Alzheimer’s disease. Ann Rev Neurosci 1986; 9: 489–512PubMedCrossRefGoogle Scholar
  95. 95.
    Brion JP. The pathology of the neuronal cytoskeleton in Alzheimer’s disease. Biochim Biophys Acta 1992; 1160: 134–42PubMedCrossRefGoogle Scholar
  96. 96.
    Klunk WE, Jacob RF, Manson RP. Quantifying amyloid by Congo red spectral assay. Methods Enzymol 1999; 309: 285–304PubMedCrossRefGoogle Scholar
  97. 97.
    Westermark GT, Johnson KH, Westermark P. Staining methods for identification of amyloid in tissue. Methods Enzymol 1999; 309: 3–25PubMedCrossRefGoogle Scholar
  98. 98.
    Robakis NK. Beta amyloid and amyloid precursor protein chemistry, molecular biology and neuropathology. In: Terry RD, Katzman R, Bick KL, editors. Alheimer disease. New York: Raven Press Ltd, 1994: 317–325Google Scholar
  99. 99.
    Selkoe DJ. Translating cell biology into therapeutic advances in Alzheimer’s disease. Nature 1999; 399(6738 Suppl.): A23–31PubMedCrossRefGoogle Scholar
  100. 100.
    Vassar R, Bennett BD, Babu-Khan S, et al. Beta-secretase cleavage of Alzheimer’s amyloid precursor protein by the transmembrane aspartic protease BACE. Science 1999; 286: 735–41PubMedCrossRefGoogle Scholar
  101. 101.
    Wolfe MS. Presenilins and γ-secretase: structure meets function. J Neurochem 2001; 76: 1615–20PubMedCrossRefGoogle Scholar
  102. 102.
    Hardy JA, Higgins GA. Alzheimer’s disease: the amyloid cascade hypothesis. Science 1992; 256: 184–5PubMedCrossRefGoogle Scholar
  103. 103.
    Gotz J, Chen F, van Dorpe J, et al. Formation of neurofibrillary tangles in P3011 tau transgenic mice induced by Abeta 42 fibrils. Science 2001; 293: 1491–5PubMedCrossRefGoogle Scholar
  104. 104.
    Milton NGN. The amyloid-β peptide binds to cyclin B1 and increases human cyclin-dependent kinase-1 activity. Neurosci Lett 2002; 322: 131–3PubMedCrossRefGoogle Scholar
  105. 105.
    Mattson MP. Cellular actions of β-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 1997; 77: 1081–132PubMedGoogle Scholar
  106. 106.
    Milton NGN. Phosphorylation of amyloid-β at the serine 26 residue by human cdc2 kinase. Neuroreport 2001; 12: 3839–44PubMedCrossRefGoogle Scholar
  107. 107.
    Buee L, Bussiere T, Buee-Scherrer V, et al. Tau protein isoforms, phosphorylation and role in neurodegenerative disorders. Brain Res Brain Res Rev 2000; 33: 95–130PubMedCrossRefGoogle Scholar
  108. 108.
    Bertram L, Blacker D, Mullin K, et al. Evidence for genetic linkage of Alzheimer’s Disease to chromosome 10q. Science 2000; 290: 2302–3PubMedCrossRefGoogle Scholar
  109. 109.
    Ertekin-Taner N, Graff-Radford N, Younkin LH, et al. Linkage of plasma Aβ42 to a quantitative locus on chromosome 10 in late-onset Alzheimer’s disease pedigrees. Science 2000; 290: 2303–4PubMedCrossRefGoogle Scholar
  110. 110.
    Myers A, Holmans P, Marshall H, et al. Susceptibility locus for Alzheimer’s disease on chromosome 10. Science 2000; 290: 2304–5PubMedCrossRefGoogle Scholar
  111. 111.
    Johansson A, Hampel H, Faltraco F, et al. Increased frequency of a new polymorphism in the cell division cycle 2 (cdc2) gene in patients with Alzheimer’s disease and frontotemporal dementia. Neurosci Lett 2003; 340: 69–73PubMedCrossRefGoogle Scholar
  112. 112.
    Milton NGN. Peptides for use in the treatment of Alzheimer’s disease. International Patent Application Publication 2002, WO 02/36614Google Scholar
  113. 113.
    Vincent I, Jicha G, Rosado M, et al. Aberrant expression of mitotic Cdc2/Cyclin Bl kinase in degenerating neurons of Alzheimer’s disease brain. J Neurosci 1997; 17: 3588–98PubMedGoogle Scholar
  114. 114.
    Rosenberger J, Petrovics G, Buzas B. Oxidative stress induces poorphanin FQ and proenkephalin gene expression in astrocytes through p38- and ERK-MAP kinases and NF-kappaB. J Neurochem 2001; 79: 35–44PubMedCrossRefGoogle Scholar
  115. 115.
    Huang X, Atwood CS, Hartshorn MA, et al. The Aβ peptide of Alzheimer’s disease directly produces hydrogen peroxide through metal ion reduction. Biochemistry 1999; 38: 7609–16PubMedCrossRefGoogle Scholar
  116. 116.
    Huang X, Cuajungco MP, Atwood CS, et al. Cu(II) potentiation of Alzheimer Aβ neurotoxicity: correlation with cell-free hydrogen peroxide production and metal reduction. J Biol Chem 1999; 274: 37111–6PubMedCrossRefGoogle Scholar
  117. 117.
    Cuajungco MP, Goldstein LE, Nunomura A, et al. Evidence that the β-amyloid plaques of Alzheimer’s disease represent the redox-silencing and entombment of Aβ by zinc. J Biol Chem 2000; 275: 19439–42PubMedCrossRefGoogle Scholar
  118. 118.
    Opazo C, Huang X, Cherny RA, et al. Metalloenzyme-like activity of Alzheimer’s disease β-amyloid: Cu-dependent catalytic conversion of dopamine, cholesterol and biological reducing agents to neurotoxic H2O2. J Biol Chem 2002; 77: 40302–8CrossRefGoogle Scholar
  119. 119.
    Tabner BJ, Turnbull S, El-Agnaf OMA, et al. Formation of hydrogen peroxide and hydroxyl radicals from Aβ and α-synuclein as a possible mechanism of cell death in Alzheimer’s disease and Parkinson’s disease. Free Radic Biol Med 2002; 32: 1076–83PubMedCrossRefGoogle Scholar
  120. 120.
    Cherny RA, Atwood CS, Xilinas X, et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer’s disease transgenic mice. Neuron 2001; 30: 665–76PubMedCrossRefGoogle Scholar
  121. 121.
    Bianca VD, Dusi S, Bianchini E, et al. β-amyloid activates O°2 forming NADPH oxidase in microglia, monocytes, and neutrophils. J Biol Chem 1999; 274: 15493–9PubMedCrossRefGoogle Scholar
  122. 122.
    Thomas T, Thomas G, McLendon C, et al. β-amyloid-mediated vasoactivity and vascular endothelial damage. Nature 1996; 380: 168–71PubMedCrossRefGoogle Scholar
  123. 123.
    Milton NGN. Anandamide and noladin ether prevent neurotoxicity of the human amyloid-β peptide. Neurosci Lett 2002; 332: 127–30PubMedCrossRefGoogle Scholar
  124. 124.
    Nakagawa T, Zhu H, Morishima N, et al. Caspase-12 mediates endoplasmic-reticulum-specific apoptosis and cytotoxicity by amyloid-β. Nature 2000; 403: 98–103PubMedCrossRefGoogle Scholar
  125. 125.
    Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer’s disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci U S A 2001; 98: 5856–61PubMedCrossRefGoogle Scholar
  126. 126.
    Plant LD, Boyle JP, Smith IF, et al. The production of amyloid β peptide is a critical requirement for the viability of central neurons. J Neurosci 2003; 23: 5531–5PubMedGoogle Scholar
  127. 127.
    Zou K, Gong J-S, Yanagisawa K, et al. A novel function of monomeric amyloid β protein serving as an antioxidant molecule against metal-induced oxidative damage. J Neurosci 2002; 22: 4833–41PubMedGoogle Scholar
  128. 128.
    Nunomura A, Perry G, Aliev G, et al. Cytosolic peroxidative damage is an early event in Alzheimer’s disease. J Neuropathol Exp Neurol 2001; 60: 759–67PubMedGoogle Scholar
  129. 129.
    Nunomura A, Perry G, Pappolla MA, et al. Neuronal oxidative stress precedes amyloid-β deposition in Down syndrome. J Neuropathol Exp Neurol 2000; 59: 1011–7PubMedGoogle Scholar
  130. 130.
    Pratico D. Alzheimer’s disease and oxygen radicals: new insights. Biochem Pharmacol 2002; 63: 563–7PubMedCrossRefGoogle Scholar
  131. 131.
    Drake J, Link CD, Butterfield DA. Oxidative stress precedes fibrillar deposition of Alzheimer’s disease amyloid β-peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiol Aging 2003; 24: 415–20PubMedCrossRefGoogle Scholar
  132. 132.
    Smith MA, Hirai K, Hsiao K, et al. Amyloid-β deposition in Alzheimer transgenic mice is associated with oxidative stress. J Neurochem 1998; 70: 2212–5PubMedCrossRefGoogle Scholar
  133. 133.
    Hillhouse EW, Reichlin S. Acetylcholine stimulates corticotrophin releasing factor secretion from primary dissociated cell cultures of rat telencephalon and diencephalon. Brain Res 1990; 506: 9–13PubMedCrossRefGoogle Scholar
  134. 134.
    Smith CD, Carney JM, Starke-Reed PE, et al. Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease. Proc Natl Acad Sci U S A 1991; 88: 10540–3PubMedCrossRefGoogle Scholar
  135. 135.
    Markesbery WR, Carney JM. Oxidative alterations in Alzheimer’s disease. Brain Pathol 1999; 9: 133–46PubMedCrossRefGoogle Scholar
  136. 136.
    Nourooz-Zadeh J, Liu EH, Yhlen B, et al. F4-isoprostanes as specific marker of docosahexaenoic acid peroxidation in Alzheimer’s disease. J Neurochem 1999; 72: 734–40PubMedCrossRefGoogle Scholar
  137. 137.
    Markesbery WR. Oxidative stress hypothesis in Alzheimer’s disease. Free Radic Biol Med 1997; 23: 134–47PubMedCrossRefGoogle Scholar
  138. 138.
    Lovell MA, Xie C, Markesbery WR. Decreased base excision repair and increased helicase activity in Alzheimer’s disease brain. Brain Res 2000; 855: 116–23PubMedCrossRefGoogle Scholar
  139. 139.
    Pratico D, Lee VMY, Trojanowski JQ, et al. Increased F2-isoprostanes in Alzheimer’s disease: evidence for enhanced lipid peroxidation in vivo. FASEB J 1998; 12: 1777–83PubMedGoogle Scholar
  140. 140.
    Aksenov M, Aksenova M, Butterfield DA, et al. Oxidative modification of creatine kinase BB in Alzheimer’s disease brain. J Neurochem 2000; 74: 2520–7PubMedCrossRefGoogle Scholar
  141. 141.
    Montine TJ, Markesberg WR, Zachert W, et al. The magnitude of brain lipid peroxidation correlates with the extent of degeneration but not with density of neurotic plaques or neurofibrillary tangles or with APOE genotype in Alzheimer’s disease patients. Am J Pathol 1999; 155: 863–8PubMedCrossRefGoogle Scholar
  142. 142.
    Lyras L, Cairns NJ, Jenner A, et al. An assessment of oxidative damage to proteins, lipids, and DNA in brain from patients with Alzheimer’s disease. J Neurochem 1997; 68: 2061–9PubMedCrossRefGoogle Scholar
  143. 143.
    Good PF, Werner P, Hsu A, et al. Evidence of neuronal oxidative damage in Alzheimer’s disease. Am J Pathol 1996; 149: 21–8PubMedGoogle Scholar
  144. 144.
    Gabbita SP, Lovell MA, Markesbery WR. Increased nuclear DNA oxidation in the brain in Alzheimer’s disease. J Neurochem 1998; 71: 2034–40PubMedCrossRefGoogle Scholar
  145. 145.
    Montine TJ, Beal MF, Cudkowicz ME, et al. Increased CSF F2-isoprostane concentration in probable Alzheimer’s disease. Neurology 1999; 52: 562–5PubMedCrossRefGoogle Scholar
  146. 146.
    Aksenova MV, Aksenov MY, Payne RM, et al. Oxidation of cytosolic proteins and expression of creatine kinase BB in frontal lobe in different neurodegenerative disorders. Dementia Geriatr Cogn Disord 1999; 10: 158–65CrossRefGoogle Scholar
  147. 147.
    Reich EE, Markesberg WE, Roberts II LJ, et al. Brain regional quantification of F-ring and D-/E-ring isoprostanes and neuroprostanes in Alzheimer’s disease. Am J Pathol 2001; 158: 293–7PubMedCrossRefGoogle Scholar
  148. 148.
    Prabico D, Clark CM, Lee VMY, et al. Increased 8, 12-iso-iPF2d-VI in Alzheimer’s disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann Neurol 2000; 48: 809–12CrossRefGoogle Scholar
  149. 149.
    Lovell MA, Ehmann WD, Butler SM, et al. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer’s disease. Neurology 1995; 45: 1594–601PubMedCrossRefGoogle Scholar
  150. 150.
    Pappolla MA, Omar RA, Kim KS, et al. Immunohistochemical evidence of antioxidant stress in Alzheimer’s disease. Am J Pathol 1992; 140: 621–8PubMedGoogle Scholar
  151. 151.
    Milton NGN. Amyloid-β binds catalase with high affinity and inhibits hydrogen peroxide breakdown. Biochem J 1999; 344: 293–6PubMedCrossRefGoogle Scholar
  152. 152.
    Resink AA, Verbeek MM, Otte-Holler I, et al. Inhibition of amyloid-β induced cell death in human brain pericytes in vitro. Brain Res 2002; 952: 111–21CrossRefGoogle Scholar
  153. 153.
    Greeve I, Hermans-Borgmeyer I, Brellinger C, et al. The human DIMINUTO/DWARFI homology Seladin-1 confers resistance to Alzheimer’s disease-associated neurodegeneration and oxidative stress. J Neurosci 2000; 20: 7345–52PubMedGoogle Scholar
  154. 154.
    Ho PI, Collins SC, Dhitavat S, et al. Homocysteine potentiates β-amyloid neurotoxicity: role of oxidative stress. J Neurochem 2001; 78: 249–53PubMedCrossRefGoogle Scholar
  155. 155.
    White AR, Huang X, Jobling MF, et al. Homocysteine potentiates copper- and amyloid beta peptide-mediated toxicity in primary cultures: possible risk factors in the Alzheimer’s-type neurodegenerative pathways. J Neurochem 2001; 76: 1509–20PubMedCrossRefGoogle Scholar
  156. 156.
    Clarke R, Smith AD, Jobst KA, et al. Folate, vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Arch Neurol 1998; 55: 1449–55PubMedCrossRefGoogle Scholar
  157. 157.
    Vatassery GT, Bauer T, Dysken M. High doses of vitamin E in the treatment of disorders of the central nervous system in the aged. Am J Clin Nutr 1999; 70: 793–801PubMedGoogle Scholar
  158. 158.
    Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. The Alzheimer’s Disease Cooperative Study. N Engl J Med 1997; 336: 1216–22PubMedCrossRefGoogle Scholar
  159. 159.
    Morris MC, Beckett LA, Scherr PA, et al. Vitamin E and vitamin C supplement use and risk of incident Alzheimer disease. Alzheimer Dis Assoc Disord 1998; 12: 121–6PubMedCrossRefGoogle Scholar
  160. 160.
    Masaki KH, Losonczy KG, Izmirlian G, et al. Association of vitamin E and C supplement use with cognitive function and dementia in elderly men. Neurology 2000; 54: 1265–72PubMedCrossRefGoogle Scholar
  161. 161.
    Murray CA, Lynch MA. Dietary supplementation with vitamin E reverses the age-related deficit in long term potentiation in dentate gyms. J Biol Chem 1998; 273: 12161–8PubMedCrossRefGoogle Scholar
  162. 162.
    Cras P, Kawai M, Siedlak S, et al. Neuronal and microglial involvement in β-amyloid protein deposition in Alzheimer’s disease. Am J Pathol 1990; 137: 241–6PubMedGoogle Scholar
  163. 163.
    Colton CA, Gilbert DL. Production of Superoxide anions by a CNS macrophage, the microglia. FEBS Lett 1987; 223: 284–8PubMedCrossRefGoogle Scholar
  164. 164.
    Guyton KZ, Liu Y, Gorospe M, et al. Activation of mitogen-activated protein kinase by H2O2: role in cell survival following oxidant injury. J Biol Chem 1996; 271: 4138–42PubMedCrossRefGoogle Scholar
  165. 165.
    Schreck R, Rieber P, Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-kB transcription factor and HIV-1. EMBO J 1991; 10: 2247–58PubMedGoogle Scholar
  166. 166.
    Premkumar DRD, Smith MA, Richey PL, et al. Induction of heme oxygenase-1 mRNA and protein in neocortex and cerebral vessels in Alzheimer’s disease. J Neurochem 1995; 65: 1399–402PubMedCrossRefGoogle Scholar
  167. 167.
    Meneilly G, Hill A. Alterations in glucose metabolism in patients with Alzheimer’s disease. J Am Geriatr Soc 1993; 41: 710–4PubMedGoogle Scholar
  168. 168.
    Keller JN, Germeyer A, Begley JG, et al. 17-β-estradiol attenuates oxidative impairment of synaptic Na+/K+-ATPase activity, glucose transport, and glutamate transport induced by amyloid β peptide and iron. J Neurosci Res 1997; 50: 522–30PubMedCrossRefGoogle Scholar
  169. 169.
    Razay G, Wilcock GK. Hyperinsulinemia and Alzheimer’s disease. Age Ageing 1994; 23: 396–9PubMedCrossRefGoogle Scholar
  170. 170.
    Craft S, Asthana S, Schellenberg GD, et al. Insulin metabolism in Alzheimer’s disease differs according to apolipoprotein E genotype and gender. Neuroendocrinology 1999; 70: 146–52PubMedCrossRefGoogle Scholar
  171. 171.
    Craft S, Peskind E, Schwartz MW, et al. Cerebrospinal fluid and plasma insulin levels in Alzheimer’s disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 1998; 50: 164–8PubMedCrossRefGoogle Scholar
  172. 172.
    Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer’s disease: implications for treatment. CNS Drugs 2003; 17: 27–45PubMedCrossRefGoogle Scholar
  173. 173.
    Guo ZH, Mattson MP. Neurotrophic factors protect cortical synaptic terminals against amyloid and oxidative stress-induced impairment of glucose transport, glutamate transport and mitochondrial function. Cereb Cortex 2000; 10: 50–7PubMedCrossRefGoogle Scholar
  174. 174.
    Offen D, Sherki Y, Melamed E, et al. Vasoactive intestinal peptide (VIP) prevents neurotoxicity in neuronal cultures: relevance to neuroprotection in Parkinson’s disease. Brain Res 2000; 854: 257–62PubMedCrossRefGoogle Scholar
  175. 175.
    Glazner GW, Boland A, Dresse AE, et al. Activity-dependent neurotrophic factor peptide (ADNF9) protects neurons against oxidative stress-induced death. J Neurochem 1999; 73: 2341–7PubMedCrossRefGoogle Scholar
  176. 176.
    Zemlyak I, Furman S, Brenneman DE, et al. A novel peptide prevents death in enriched neuronal cultures. Regul Pept 2000; 96: 39–43PubMedCrossRefGoogle Scholar
  177. 177.
    Cheepsunthorn P, Palmer C, Connor JR. Cellular distribution of ferritin subunits in postnatal rat brain. J Comp Neurol 1998; 400: 73–86PubMedCrossRefGoogle Scholar
  178. 178.
    Hulet SW, Powers S, Connor JR. Distribution of transferrin and ferritin binding in normal and multiple sclerotic human brains. J Neurol Sci 1999; 165: 48–55PubMedCrossRefGoogle Scholar
  179. 179.
    Good PF, Perl DP, Bierer LM, et al. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer’s disease: a laser microprobe (LAMMA) study. Ann Neurol 1992; 31: 286–92PubMedCrossRefGoogle Scholar
  180. 180.
    Focht SJ, Synder BS, Beard JL, et al. Regional distribution of iron, transferrin, ferritin and oxidatively-modified proteins in young and aged Fischer 344 rat brains. Neuroscience 1997; 79: 255–61PubMedCrossRefGoogle Scholar
  181. 181.
    Lovell MA, Robertson JD, Teesdale WJ, et al. Copper, iron and zinc in Alzheimer’s disease senile plaques. J Neurol Sci 1998; 158: 47–52PubMedCrossRefGoogle Scholar
  182. 182.
    Sayre LM, Perry G, Harris PLR, et al. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer’s disease: a central role for bound transition metals. J Neurochem 2000; 74: 270–9PubMedCrossRefGoogle Scholar
  183. 183.
    Bush AI, Huang X, Fairlie DP. The possible origin of free radicals from amyloid β peptides in Alzheimer’s disease. Neurobiol Aging 1999; 20: 335–7CrossRefGoogle Scholar
  184. 184.
    Cherny RA, Legg JT, McLean CA, et al. Aqueous dissolution of Alzheimer’s disease Abeta amyloid deposits by biometal depletion. J Biol Chem 1999; 274: 23223–8PubMedCrossRefGoogle Scholar
  185. 185.
    Abreo K, Abreo F, Sella ML, et al. Aluminum enhances iron uptake and expression of neurofibrillary tangle protein in neuroblastoma cells. J Neurochem 1999; 72: 2059–64PubMedCrossRefGoogle Scholar
  186. 186.
    Smith MA, Harris PLR, Sayre LM, et al. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc Natl Acad Sci U S A 1997; 94: 9866–72PubMedCrossRefGoogle Scholar
  187. 187.
    Oteiza PI. A mechanism for the stimulatory effect of aluminum on iron-induced lipid peroxidation. Arch Biochem Biophys 1994; 308: 374–9PubMedCrossRefGoogle Scholar
  188. 188.
    Butterfield DA, Hensley K, Harris M, et al. β-amyloid peptide free radical fragments initiate synaptosomal lipoperoxidation in a sequence specific fashion: implications to Alzheimer’s disease. Biochem Biophys Res Commun 1994; 200: 710–5PubMedCrossRefGoogle Scholar
  189. 189.
    Hensley K, Carney JM, Mattson MP, et al. A model for β-amyloid aggregation and neurotoxicity based on free radical generation by the peptide: relevance to Alzheimer disease. Proc Natl Acad Sci U S A 1994; 91: 3270–4PubMedCrossRefGoogle Scholar
  190. 190.
    Sayre LM, Zagorski MG, Surewicz WK, et al. Mechanisms of neurotoxicity associated with amyloid β deposition and the role of free radicals in the pathogenesis of Alzheimer’s disease: a critical appraisal. Chem Res Toxicol 1997; 10: 518–26PubMedCrossRefGoogle Scholar
  191. 191.
    Dikalov SI, Vitek MP, Maples KR, et al. Amyloid β-peptides do not form peptide-derived free radicals spontaneously but can enhance metal-catalyzed oxidation of hydroxylamines to nitroxides. J Biol Chem 1999; 274: 9392–9PubMedCrossRefGoogle Scholar
  192. 192.
    Rottkamp CA, Raina AK, Zhu X, et al. Redox-active iron mediates amyloid-β toxicity. Free Radic Biol Med 2001; 30: 447–50PubMedCrossRefGoogle Scholar
  193. 193.
    Schubert D, Chevion M. The role of iron in beta amyloid toxicity. Biochem Biophys Res Commun 1995; 216: 702–7PubMedCrossRefGoogle Scholar
  194. 194.
    Zhang Z, Rydel RE, Drzewiecki GJ, et al. Amyloid β-mediated oxidative and metabolic stress in rat cortical neurons: no direct evidence for a role for H2O2 generation. J Neurochem 1996; 67: 1595–606PubMedCrossRefGoogle Scholar
  195. 195.
    Milton NGN, Mayor NP, Rawlinson J. Identification of amyloid-β binding sites using an antisense peptide approach. Neuroreport 2001; 12: 2561–6PubMedCrossRefGoogle Scholar
  196. 196.
    Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele e4 with late-onset familial and sporadic Alzheimer’s disease. Neurology 1993; 43: 1467–72PubMedCrossRefGoogle Scholar
  197. 197.
    Miyata M, Smith JD. Apolipoprotein E allelle-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β-amyloid peptides. Nat Genet 1996; 14: 55–61PubMedCrossRefGoogle Scholar
  198. 198.
    Halliwell B, Gutteridge JM. Oxygen toxicity, oxygen radicals, transition metals and disease. Biochem J 1984; 219: 1–14PubMedGoogle Scholar
  199. 199.
    Wasantwisut E. Nutrition and development: other micronutrients’ effect on growth and cognition. Southeast Asian J Trop Med Public Health 1997; 2: 78–82Google Scholar
  200. 200.
    Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. Methods Enzymol 1990; 186: 1–85PubMedCrossRefGoogle Scholar
  201. 201.
    Stokes AH, Hastings TG, Vrana KE. Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 1999; 55: 659–65PubMedCrossRefGoogle Scholar
  202. 202.
    Graham DG, Tiffany SM, Bell Jr WR, et al. Autoxidation versus covalent binding of quinines as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol Pharmacol 1978; 14: 644–53PubMedGoogle Scholar
  203. 203.
    Halliwell B. Manganese ions, oxidation reactions and the super-oxide radical. Neurotoxicology 1984; 5: 113–7PubMedGoogle Scholar
  204. 204.
    Puppo A, Halliwell B. Formation of hydroxyl radicals in biological systems: does myoglobin stimulate hydroxyl radical formation from hydrogen peroxide? Free Radic Res Commun 1988; 4: 415–22PubMedCrossRefGoogle Scholar
  205. 205.
    Harel S, Salan MA, Kanner J. Iron release from metmyoglobin, methaemoglobin and cytochrome c by a system generating hydrogen peroxide. Free Radic Res Commun 1988; 5: 11–9PubMedCrossRefGoogle Scholar
  206. 206.
    Alayash AI. Hemoglobin-based blood substitutes and the hazards of blood radicals. Free Radic Res 2000; 33: 341–8PubMedCrossRefGoogle Scholar
  207. 207.
    Evans PJ, Akanmu D, Halliwell B. Promotion of oxidative damage to arachidonic acid and alpha 1-antiproteinase by anti-inflammatory drugs in the presence of the haem proteins myoglobin and cytochrome c. Biochem Pharmacol 1994; 48: 2173–9PubMedCrossRefGoogle Scholar
  208. 208.
    Gutteridge JM, Smith A. Antioxidant protection by haemopexin of haem-stimulated lipid peroxidation. Biochem J 1998; 256: 861–5Google Scholar
  209. 209.
    Macdonald RL, Weir BK. A review of hemoglobin and the pathogenesis of cerebral vasospasm. Stroke 1991; 22: 971–82PubMedCrossRefGoogle Scholar
  210. 210.
    Bush AI. Metal complexing agents as therapies for Alzheimer’s disease. Neurobiol Aging 2002; 23: 1031–8PubMedCrossRefGoogle Scholar
  211. 211.
    Rogers JT, Randall JD, Cahill CM, et al. An iron-responsive element type II in the 5′-untranslated region of the Alzheimer’s amyloid precursor protein transcript. J Biol Chem 2002; 277: 45518–28PubMedCrossRefGoogle Scholar
  212. 212.
    Atwood CS, Scarpa RC, Huang X, et al. Characterization of copper interactions with Alzheimer amyloid β peptides: identification of an attomolar-affinity copper binding site on amyloid β1–42. J Neurochem 2000; 75: 1219–33PubMedCrossRefGoogle Scholar
  213. 213.
    Multhaup G, Ruppert T, Schlicksupp A, et al. Copper-binding amyloid precursor protein undergoes a site-specific fragmentation in the reduction of hydrogen peroxide. Biochemistry 1998; 37: 7224–30PubMedCrossRefGoogle Scholar
  214. 214.
    Mattson MP, Carney JW, Butterfield DA. A tombstone in Alzheimer’s? [letter]. Nature 1995; 373: 481PubMedCrossRefGoogle Scholar
  215. 215.
    Smith MA, Sayre LM, Vitek MP, et al. Early AGEing and Alzheimer’s [letter]. Nature 1995; 374: 316PubMedCrossRefGoogle Scholar
  216. 216.
    Ledesma MD, Bonay P, Colaco C, et al. Analysis of microtubule-associated protein tau glycation in paired helical filaments. J Biol Chem 1994; 269: 21614–9PubMedGoogle Scholar
  217. 217.
    Sayre LM, Zelasko DA, Harris PLR, et al. 4-Hydroxynonenalderived advanced lipid peroxidation end products are increased in Alzheimer’s disease. J Neurochem 1997; 68: 2092–7PubMedCrossRefGoogle Scholar
  218. 218.
    Smith MA, Sayre LM, Monnier VM, et al. Radical AGEing in Alzheimer’s disease. Trends Neurosci 1995; 18: 172–6PubMedCrossRefGoogle Scholar
  219. 219.
    Smith MA, Rudnicka-Nawrot M, Richey PL, et al. Carbonylrelated posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer’s disease. J Neurochem 1995; 64: 2660–6PubMedCrossRefGoogle Scholar
  220. 220.
    Smith MA, Perry G, Richey PL, et al. Oxidative damage in Alzheimer’s. Nature 1996; 382: 120–1PubMedCrossRefGoogle Scholar
  221. 221.
    Smith MA, Harris PLR, Sayre LM, et al. Widespread peroxynitrite-mediated damage in Alzheimer’s disease. J Neurosci 1997; 17: 2653–7PubMedGoogle Scholar
  222. 222.
    Vitek MP, Bhattacharya K, Glendening JM, et al. Advanced glycation end products contribute to amyloidosis in Alzheimer disease. Proc Natl Acad Sci U S A 1994; 91: 4766–70PubMedCrossRefGoogle Scholar
  223. 223.
    Yan S-D, Chen X, Schmidt A-M, et al. Glycated tau protein in Alzheimer disease: a mechanism for induction of oxidant stress. Proc Natl Acad Sci U S A 1994; 91: 7787–91PubMedCrossRefGoogle Scholar
  224. 224.
    McGeer PL, Rogers J. Anti-inflammatory agents as a therapeutic approach to Alzheimer’s disease. Neurology 1992; 42: 447–9PubMedCrossRefGoogle Scholar
  225. 225.
    Rich JB, Rasmusson DX, Folstein MF, et al. Nonsteroidal anti-inflammatory drugs in Alzheimer’s disease. Neurology 1995; 45: 51–5PubMedCrossRefGoogle Scholar
  226. 226.
    Rogers J, Kirby LC, Hempelman SR, et al. Clinical trial of indomethacin in Alzheimer’s disease. Neurology 1993; 43: 1609–11PubMedCrossRefGoogle Scholar
  227. 227.
    Stewart WF, Kawas C, Corrada M, et al. Risk of Alzheimer’s disease and duration of NSAID use. Neurology 1997; 48: 626–31PubMedCrossRefGoogle Scholar
  228. 228.
    McGeer EG, McGeer PL. Inflammatory cytokines in the CNS: possible role in the pathogenesis of neurodegenerative disorders and therapeutic implications. CNS Drugs 1997; 7: 214–38CrossRefGoogle Scholar
  229. 229.
    Marsicano G, Moosmann B, Hermann H, et al. Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1. J Neurochem 2002; 80: 448–56PubMedCrossRefGoogle Scholar
  230. 230.
    Boscoboinik D, Szewczyk A, Hensey C, et al. Inhibition of cell proliferation by α-tocopherol. J Biol Chem 1991; 266: 6188–94PubMedGoogle Scholar
  231. 231.
    Chao CC, Lee EH. Neuroprotective mechanism of glial cell line-derived neurotrophic factor on dopamine neurons: role of antioxidation. Neuropharmacology 1999; 38: 913–6PubMedCrossRefGoogle Scholar
  232. 232.
    Hou JG, Cohen G, Mytilineou C. Basic fibroblast growth factor stimulation of glial cells protects dopamine neurons from 6-hydroxydopamine toxicity: involvement of the glutathione system. J Neurochem 1997; 69: 76–83PubMedCrossRefGoogle Scholar
  233. 233.
    Kontush A, Berndt C, Weber W, et al. Amyloid-β is an antioxidant for lipoproteins in cerebrospinal fluid and plasma. Free Radic Biol Med 2001; 30: 119–28PubMedCrossRefGoogle Scholar
  234. 234.
    Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999; 400: 173–7PubMedCrossRefGoogle Scholar
  235. 235.
    Check E. Battle of the mind. Nature 2003; 422: 370–2PubMedCrossRefGoogle Scholar
  236. 236.
    Kitani K, Kanai S, Ivy GO, et al. Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effects of deprenyl: a possible antioxidant strategy. Mech Ageing Dev 1999; 111: 211–21PubMedCrossRefGoogle Scholar
  237. 237.
    Marshall KA, Reiter RJ, Poeggeler B, et al. Evaluation of the antioxidant activity of melatonin in vitro. Free Radic Biol Med 1996; 21: 307–15PubMedCrossRefGoogle Scholar
  238. 238.
    Reiter RJ, Cabrera J, Sainz RM, et al. Melatonin as a pharmacological agent against neuronal loss in experimental models of Huntington’s disease, Alzheimer’s disease and parkinsonism. Ann N Y Acad Sci 1999; 890: 471–85PubMedCrossRefGoogle Scholar
  239. 239.
    Chyan YJ, Poeggeler B, Omar RA, et al. Potent neuroprotective properties against the Alzheimer beta-amyloid by an endogenous melatonin-related indole structure, indole-3-propionic acid. J Biol Chem 1999; 274: 21937–42PubMedCrossRefGoogle Scholar
  240. 240.
    Schonberger SJ, Edgar PF, Kydd R, et al. Proteomic analysis of the brain in Alzheimer’s disease: molecular phenotype of a complex disease process. Proteomics 2001; 1: 1519–28PubMedCrossRefGoogle Scholar
  241. 241.
    Sramek JJ, Cutler NR. Recent developments in the drug treatment of Alzheimer’s disease. Drugs Aging 1999; 14: 359–73PubMedCrossRefGoogle Scholar
  242. 242.
    Bush AI, Tanzi RE, Xilinas M, et al. Use of clioquinol for the therapy of Alzheimer’s disease. US Patent Application Publication 002002594. 2002Google Scholar
  243. 243.
    Kaur D, Yantiri F, Rajagopalan S, et al. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson’s disease. Neuron 2003; 37: 1–20CrossRefGoogle Scholar
  244. 244.
    Cole GM. Ironic fate: can a banned drug control metal heavies in neurodegenerative diseases? Neuron 2003; 37: 889–90PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2004

Authors and Affiliations

  1. 1.Department of Clinical Neurosciences, Royal Free & University College Medical SchoolUniversity College LondonLondonUK

Personalised recommendations